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Abstract
Bone morphogenetic protein (BMP)-evoked reorientation and chemotaxis of cells occurs with rapid onset and involves
events local to the cell membrane. The signaling pathways underlying these rapid processes likely diverge from those
mediating classical transcriptional responses to BMPs but it remains unclear how BMP receptors are utilized to generate
distinct intracellular mechanisms. We show that BMP7-evoked chemotaxis of monocytic cells depends on the activity of
canonical type II BMP receptors. Although the three canonical type II BMP receptors are expressed in monocytic cells,
inhibition of receptor subunit expression by RNAi reveals that ActRIIA and BMPRII, but not ActRIIB, are each essential for
BMP7-evoked chemotaxis but not required individually for BMP-mediated induction. Furthermore, the chemotactic
response to BMP7 does not involve canonical Smad4-dependent signaling but acts through PI3K-dependent signaling,
illustrating selective activation of distinct intracellular events through differential engagement of receptors. We suggest a
model of a BMP receptor complex in which the coordinated activity of ActRIIA and BMPRII receptor subunits selectively
mediates the chemotactic response to BMP7.
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Introduction
Many growth factors originally characterized for their trophic
functions, involving transcriptional activity in target cells, appear
also to evoke spatially restricted, tropic events which depend
on short latency local regulation of cytoskeletal dynamics [1,2].
Both trophic and tropic responses can occur in the same cells,
raising the question of how the same stimulus activates distinct
intracellular signaling programs.
Bone morphogenetic proteins (BMPs) represent such a class of
signaling molecules. Classical BMP-evoked gene induction and
cellular differentiation occurs widely [3] and the canonical
receptors and downstream signaling pathways that give rise to
these trophic events have been described in detail [4,5]. Tropic
responses to BMPs include chemotaxis, described in many cell
types and tissues [6–10], and reorientation of neuronal growth
cones [11–13], both events result from localized changes in
membrane and cytoskeletal organization [14,15]. However,
although evidence is emerging for an array of non-canonical
BMP signaling mechanisms [13,16–18], it remains unclear how
BMPs initiate local cytoskeletal signaling, whether components of
the inductive signaling pathway also mediate tropic signaling and
how downstream signaling choice is regulated.
Evidence from in vitro assays on primary migrating cells or
embryonic spinal neurons suggests that divergence of chemotropic
and inductive signaling responses to BMPs, within the same cells,
occurs at the receptor level. Thus, of the BMPs with neural
inducing capacity, only a subset is active in growth cone orien-
tation [11,12]. Moreover, BMP7 shows different potencies in
chemotropic versus induction assays [7,11]. Classically, BMP
signal transduction is initiated by dimers of BMP binding to a
tetrameric receptor complex comprising one pair each of type I
(ALK2, BMPRIA or BMPRIB) and type II (ActRIIA, ActRIIB or
BMPRII) BMP receptor subunits [5,19]. The potential for variety
in the composition of receptor complexes raises the possibility that
a subset of BMPs selectively recruit individual receptor subunits
that drive chemotropic responses.
There is growing evidence for divergent mechanisms down-
stream of receptor activation by BMPs. BMP-mediated induction
of gene expression depends on long exposure time, whereas BMP7
acts within minutes to elicit chemotaxis or growth cone collapse
[7,11], suggesting that the underlying intracellular mechanism
activating chemotaxis does not rely on transcription. Divergence
from the canonical intracellular signaling pathway may lie
somewhere along the BMP-evoked Smad signaling cascade, which
includes receptor-regulated Smads (R-Smads) specific to BMPs
(Smad1, Smad5 and Smad8) and the co-Smad, Smad4 [5,20], or
might occur independent of Smad-mediated signaling in direct
response to receptor activation. Recently, R-Smad-independent
mechanisms of BMP signal transduction have been shown to
regulate transcription downstream of receptor activation [21,22]
but have also been implicated in non-transcriptional mechanisms
[4,23]. In particular, phosphoinositide 3-kinase (PI3K) and LIM
kinase 1 (LIMK1), regulators of cytoskeletal dynamics, have both
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[24,25], providing a link between BMP receptor activation and
cytoskeletal signaling. Activation of PI3K-dependent signaling by
BMPs has been implicated in the migration of chondrosarcoma
and other cells [17,18]. Moreover, the identification of PI3K as a
common and critical target of other, non-BMP, chemotactic
factors [26–29], positions this kinase as a potential direct target of
BMPs in chemotaxis and other BMP-dependent chemotropic
activities.
We have used the chemotaxis of monocytic cells as a model cell
system in which to dissect the differential signaling mechanisms
underlying chemotactic and inductive responses to a given BMP.
Because of the link between type II receptor subunits and the
cytoskeleton, we have focused our attention on the potential role of
type II BMP receptor subunits in chemotaxis and provide evidence
for a model in which ActRIIA and BMPRII subunits, acting in
unique combination, possibly as a heterodimer pair, are key
players in the chemotactic response to BMP7. Other type II
receptor subunit homo- or heterodimer combinations, involving
ActRIIB, do not appear to support and are not essential to the
chemotactic response. The selective dependence on individual
type II BMP receptors in chemotaxis is not exhibited by the
inductive activities of BMP7. Moreover, although the classical
signaling pathway involving Smads is activated by BMP7 in these
cells and results in gene induction, we show that BMP7-evoked
chemotaxis is independent of the Smad4-mediated signaling
cascade and depends on PI3K activity. Our results support a
model in which the selective engagement of a receptor complex
containing both ActRIIA and BMPRII subunits by chemotropic
BMPs, typified by BMP7, directs a divergent intracellular pathway
towards rapid activation of local cytoskeletal dynamics.
Results
BMP7 Stimulates a Chemotactic Response in WEHI 274.1
Cells
To study the mechanisms underlying the rapid, chemotropic
effects of BMPs, we tested the chemotactic responses of two
monocytic cell lines, mouse WEHI 274.1 cells and human THP-1
cells. Transwell chemotaxis assays were used to measure the
migration of cells from the upper to the lower chamber, across a
5 mm pore filter, in response to candidate chemotactic agents. The
response was measured as the number of cells that migrated into
the transwell filter pores normalized to the number of cells in the
pores under control conditions, providing a chemotactic index
(CI). BMP7 in the lower chamber evoked migration of WEHI
274.1 and THP-1 cells (Figures 1A and S1, respectively). The
responses to 10 pg/ml BMP7 (WEHI 274.1: CI=93+/238,
Figure 1A; THP-1: CI=125+/231, Figure S1) were comparable
to the response to the standard chemotactic agent, Monocyte
Chemotactic Protein-1 (MCP-1) at 100 ng/ml (WEHI 274.1:
CI=139+/245, Figure 1A; THP-1: CI=71+/218, Figure S1).
BMP7 showed a biphasic activity profile, with peak chemotactic
activity at 1 pg/ml (CI=236+/221; Figure 1B). The effects of
neutralizing and reversing the BMP7 gradient at all concentrations
tested confirmed that the response represents directed migration,
or chemotaxis, rather than activation of non-directional chemo-
kinetic activity (Table S1).
A Subset of BMPs Exhibit Chemotactic Activity
To gain insight into the ligand/receptor relationships of
chemotropic BMPs, we examined the profile of BMPs that
evoke chemotaxis. We tested a range of BMPs belonging to
different subgroups based on structural similarity [30,31]. BMP6,
a member of the BMP5/6/7 structural subgroup, BMP2 and
BMP4, from the BMP2/4 subgroup, and GDF7, representing the
GDF5/6/7 subgroup, were all tested, initially at 10 pg/ml. BMP2
stimulated chemotaxis in WEHI 274.1 cells (CI=116+/240;
Figure 1A) and THP-1 cells (CI=89+/221; Figure S1), as did
BMP4 in WEHI 274.1 cells (J. C. Perron and J. Dodd,
unpublished). In contrast, BMP6 (WEHI 274.1: CI=223+/26;
THP-1: CI=4+/217) and GDF7 (WEHI 274.1: CI=10+/210;
THP-1: CI=6+/210,) were unable to stimulate monocytic cell
chemotaxis (Figures 1A and S1). The similarity of the pattern of
responses of the mouse and human monocytic cells to BMPs, and
the close resemblance of the BMP7 responses in the two cell lines
to those observed with primary monocytes [7], led us to focus on
only one of the lines, WEHI 274.1, for all further experiments
described below.
Figure 1. Chemotaxis of monocytic cells in response to a panel
of BMPs. A: WEHI 274.1 cell migration through transwell chamber
filters in response to 10 pg/ml BMP7, BMP2, BMP6 or GDF7 in the lower
chamber. For comparison, cells were also stimulated with MCP-1
(100 ng/ml). The chemotaxis index (CI) is shown as mean +/2 SEM.
MCP-1 (CI=139+/245, n=4); BMP7 (CI=93+/238, n=5); BMP2
(CI=116+/240, n=4); BMP6 (CI=223+/26, n=3); GDF7 (CI=10+/2
10, n=3). B: Dose response curves for chemotaxis of WEHI 274.1 cells in
response to BMP7, BMP6 and GDF7 (n$3 for each protein at each
concentration). Migration in the presence of BMP7 differs significantly
from migration in the presence of BMP6 or of GDF7; (*) p,0.05; (**)
p,0.01; (***) p,0.002 (Student’s t test).
doi:10.1371/journal.pone.0008198.g001
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chemotaxis resulted from differences in potency, dose response
curves were performed using BMP6, GDF7, BMP7, BMP4
and BMP2 over a wide range of concentrations (10 fg/ml–
100 ng/ml [0.3 fM–0.3 nM]). BMP2 and BMP4 both mimicked
BMP7, showing a biphasic dose response curve (J. C. Perron and J.
Dodd, unpublished). In contrast, neither BMP6 nor GDF7
stimulated WEHI 274.1 cell chemotaxis at any concentration
tested (Figure 1B).
Both BMP6 and GDF7 are known to have inductive activity in
neural tissue in vitro [32]. Therefore, in control experiments, to
confirm that these BMPs were active, we tested for BMP-induced
expression of the LIM HD transcription factor, LH2, in explants
of chick neural tube, as previously described [33]. BMP6 and
GDF7 both induced robust expression of LH2 that was
indistinguishable from that induced by BMP7 (Figure S2A). We
then tested whether BMP6, BMP7 and GDF7 activate the classical
signaling pathway in WEHI 274.1 cells, by measuring the
phosphorylation of R-Smads by Western blot analysis of BMP-
treated WEHI 274.1 cell extracts. All three BMPs promoted R-
Smad phosphorylation, to similar levels, in WEHI 274.1 cells
(Figure S2B). Thus, although BMP6, BMP7 and GDF7 share the
ability to stimulate early classical transduction events downstream
of canonical BMP receptor binding, BMP6 and GDF7 are unable
to activate the chemotactic response.
Together, these initial experiments in WEHI 274.1 and THP-1
cells demonstrate a BMP-evoked chemotropic activity that exhibits
agonist selectivity. The profile of chemotactic activity among
BMPs suggests that the composition of the receptor complexes and
downstream signaling pathways underlying the chemotactic
response are distinct from those mediating transcriptional
responses to BMPs. Nonetheless, it remains unclear whether these
pathways comprise non-classical transduction components or
include classical components, commandeered to elicit chemotropic
responses.
Canonical Type II BMP Receptors Are Required for the
Chemotactic Response of WEHI 274.1 Cells to BMP7
To determine whether canonical BMP receptors mediate
chemotropic responses to BMPs, and in light of the noted
association of type II BMP receptors with cytoskeletal signaling
elements, we focused on the roles of type II BMP receptors in
BMP7-evoked chemotaxis. We first determined which type II
BMP receptor subunits are expressed by WEHI 274.1 cells, using
RT-PCR analysis to detect BMP receptor mRNA. All three
known type II BMP receptor subunits, ActRIIA, ActRIIB and
BMPRII, were found to be expressed in WEHI 274.1 cells
(Figure 2).
To examine the requirement for type II BMP receptors in
BMP7-evoked WEHI 274.1 cell chemotaxis, we tested the effect of
blocking expression of individual receptor subunits by RNAi. To
do so, we developed short hairpin RNA (shRNA) vectors targeting
mouse ActRIIA-, ActRIIB- and BMPRII-specific sequences and also
encoding for GFP to label shRNA-expressing cells. BMP receptor
shRNAs were electroporated individually into WEHI 274.1 cells
(
DWEHI), which were sorted to enrich for the GFP-expressing
population. As a negative control, WEHI 274.1 cells were
electroporated with a shRNA that targets mRNA encoding the
red fluorescent protein, dsRed (sh-dsRed). Quantitative PCR
(QPCR) was used to measure the effects of expressing subunit-
specific shRNAs on endogenous levels of type II receptor mRNA
in WEHI 274.1 cells (Figure 3). Compared with BMP receptor
mRNA levels in dsRed
DWEHI cells, each type II BMP receptor
shRNA significantly inhibited expression of its target receptor in
sorted WEHI 274.1 cells: sh-AIIA (70% reduction of ActRIIA
mRNA; Figure 3A), sh-AIIB (60% reduction of ActRIIB mRNA;
Figure 3B) and sh-BRII (46% reduction of BMPRII mRNA;
Figure 3C). Expression of individual BMP receptor shRNAs had
no significant effect on the relative levels of non-target type II
BMP receptor mRNA expression (Figure 3).
It was not possible to measure commensurate regulation of
endogenous receptor subunit protein in WEHI 274.1 cells because
antibodies that are selective for individual type II BMP receptor
subunits detected protein only at levels achieved by transient over
expression. The effect of each shRNA construct on type II BMP
receptor subunit protein expression was therefore tested by co-
transfection with target and non-target receptor cDNAs in HEK
293 cells. Receptor subunit expression was measured on Western
blots of transfected cell lysates. Heterologous expression of BMP
receptor protein was unaffected by co-expression with sh-dsRed
compared with empty vector (pLL3.7) controls (Figure S3). In
contrast, co-transfection of sh-AIIA, sh-AIIB and sh-BRII reduced
target protein expression effectively (Figure S4A, S4E, S4I,
respectively). Moreover, as was shown for mRNA in WEHI
274.1 cells, each shRNA was target specific and did not cause a
reduction in the expression of non-target BMP receptor proteins
(Figure S4). Thus, shRNA expression in WEHI 274.1 or HEK 293
cells effectively and selectively reduced expression of each of the
three type II BMP receptor subunits.
We then asked whether the reduction of expression of individual
receptor subunits changes the response of WEHI 274.1 cells to
BMP7. WEHI 274.1 cells expressing either type II BMP receptor
shRNAs or sh-dsRed were tested in chemotaxis and Smad
phosphorylation assays. We found that sh-AIIA eliminated the
chemotactic response to BMP7 (CI=23+/26; Figure 4A)
compared to the response in dsRed
DWEHI cells (CI=66+/29;
Figure 4A). sh-BRII also effectively inhibited BMP7-evoked
chemotaxis (73% reduction; CI=18+/24; Figure 4A). Expression
of sh-AIIB, however, had no effect on the response of WEHI 274.1
cells to BMP7 (17% reduction; CI=55+/23; Figure 4A). In
control experiments, using MCP-1 as an agonist, ActRIIA
D
2,
ActRIIB
D2 and BMPRII
DWEHI cells all showed normal
chemotactic responses (Figure 4B).
To determine whether other BMP responses were affected by
loss of individual type II receptors, in particular, ActRIIA or
BMPRII, we examined the ability of BMP7 to stimulate
phosphorylation of R-Smads in ActRIIA
D2, ActRIIB
D2 and
BMPRII
DWEHI cells. Phosphorylation was unchanged in all three
knockdown conditions compared to control, dsRed
DWEHI cells
Figure 2. Type II BMP receptor mRNA expression in WEHI 274.1
cells. cDNA from WEHI 274.1 cells transcribed from total RNA in the
presence (top, +RT) and absence (middle, -RT) of reverse transcriptase
and amplified with BMP receptor subunit-specific primers. Plasmids
encoding type II BMP receptor cDNAs (bottom, Plasmid DNA) were used
as a positive control for each primer set. The sizes of the expected
reaction products are 702 bp for ActRIIA, 928 bp for ActRIIB, and
813 bp for BMPRII.
doi:10.1371/journal.pone.0008198.g002
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cells by receptor-targeted shRNAs. Real-time QPCR analysis of
dsRed
D2, ActRIIA
D2, ActRIIB
D2 and BMPRII
DWEHI cells. Results are
expressed as the percent of control (mean +/2 SEM) for each condition
relative to BMP receptor mRNA levels in dsRed
DWEHI (control) cells
(n=2). A: ActRIIA mRNA expression in the presence of sh-AIIA (32%+/
21%), sh-AIIB (95%+/214%) or sh-BRII (115%+/27%). B: ActRIIB mRNA
expression in the presence of sh-AIIA (85%+/22%), sh-AIIB (41%+/
211%) or sh-BRII (137%+/236%). C: BMPRII mRNA expression in the
presence of sh-AIIA (117%+/215%), sh-AIIB (124%+/216%) or sh-BRII
(55%+/29%). Individual type II BMP receptor shRNAs modulated target
mRNAs selectively, but had no significant effect on the expression level
of non-target BMP receptor mRNA.
doi:10.1371/journal.pone.0008198.g003
Figure 4. BMP7-stimulated WEHI 274.1 cell chemotaxis follow-
ing type II BMP receptor knockdown. Chemotaxis of dsRed
D2,
ActRIIA
D2, ActRIIB
D2 and BMPRII
DWEHI cells (mean +/2 SEM) in
response to BMP7 (10 pg/ml, A) or MCP-1 (100 ng/ml, B). In A,
dsRed
DWEHI (CI=66+/29; n=8), ActRIIA
DWEHI (CI=23+/26; n=3),
ActRIIB
DWEHI (CI=55+/23; n=4) and BMPRII
DWEHI cells (CI=18+/24;
n=7). n=3 for each condition in B. BMP7-stimulated chemotaxis
following knockdown with either sh-AIIA or sh-BRII differs significantly
from that in dsRed
DWEHI (control) cells; (**) p,0.0001 (Student’s t test).
doi:10.1371/journal.pone.0008198.g004
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canonical type II BMP receptor subunits, ActRIIA and BMPRII,
are both required for BMP7-evoked chemotaxis but that ActRIIB
is not required. In contrast, this requirement and selectivity for the
function of individual receptors is not reflected in the activation of
the classical Smad-dependent pathway in response to BMP7,
where receptor activity may be redundant [34].
Actriib Cannot Rescue BMP7-Evoked Chemotaxis
Following Knockdown of Actriia Expression
Although the results of the RNAi experiments revealed a
selective requirement in BMP7-evoked chemotaxis for ActRIIA
and BMPRII receptor subunits, the question remained whether
ActRIIB has the ability to mediate the chemotactic response to
BMP7. We therefore tested whether exogenously expressed mouse
ActRIIB is sufficient to compensate for the loss of ActRIIA in
WEHI 274.1 cells. The selectivity of each shRNA reagent for its
target mRNA, endogenously expressed in WEHI 274.1 cells or
heterologously expressed in transfected in HEK 293 cells (see
Figures 3 and S4), made such a rescue assay feasible.
To develop the assay, we first demonstrated that over expression
of ActRIIA, ActRIIB or BMPRII in dsRed
DWEHI cells did not
affect the baseline chemotactic response of the cells to BMP7
(Figure 5A, lanes 3–5). Next, we tested the ability of wild-type
mouse ActRIIA and sh-AIIA-resistant ActRIIA mutant cDNAs to
rescue BMP7-stimulated chemotaxis in ActRIIA
DWEHI cells.
Expression levels of ActRIIA protein generated by wild-type and
shRNA-resistant cDNAs were measured in parallel by Western
blot analysis of COS-1 cell lysates co-transfected with sh-AIIA.A s
shown earlier in HEK 293 cells (see Figure S4A), ActRIIA protein
was almost undetectable in COS-1 cells co-expressing wild-type
ActRIIA and sh-AIIA (Figure S6), confirming susceptibility to the
shRNA. In contrast, co-transfection of sh-AIIA-resistant ActRIIA
cDNAs (ActRIIA-RES-1V and ActRIIA-RES-3V) with sh-AIIA
permitted ActRIIA protein expression at levels similar to that in
sh-dsRed-transfected cells (Figure S6). In chemotaxis assays, co-
expression of control vector (pcDNA3) had no effect on the normal
response to BMP7 in dsRed
DWEHI cells (Figure 5A, lanes 1 and
2) or the loss of chemotaxis observed in ActRIIA
DWEHI cells
(Figure 5A, lanes 6 and 7). In contrast, co-expression of exogenous
wild-type mouse ActRIIA with sh-AIIA in WEHI 274.1 cells
resulted in a minor recovery of chemotaxis compared to that in
control cells (,40% recovery of CI; Figure 5A, lane 8). Moreover,
co-expression of sh-AIIA-resistant ActRIIA cDNA mutants re-
stored BMP7-evoked chemotaxis, despite the presence of the
potent sh-AIIA shRNA. ActRIIA
DWEHI cells co-expressing
ActRIIA-RES-1V showed an intermediate response (,50%
recovery of CI) and co-expression of ActRIIA-RES-3V, resulted
in almost full rescue (,90% recovery of CI) of BMP7-evoked
chemotaxis (Figure 5A, lanes 9 and 10, respectively). Thus,
restoration of ActRIIA expression was sufficient to overcome sh-
AIIA-mediated inhibition of the chemotactic response to BMP7.
We then tested whether over expression of ActRIIB protein is
able to rescue the chemotactic response to BMP7 in WEHI 274.1
cells in which endogenous ActRIIA has been selectively silenced.
Transient transfection in HEK 293 cells resulted in strong
expression of ActRIIB receptor protein which was not affected
by co-transfection of sh-AIIA (see Figure S4D). However,
expression of exogenous ActRIIB in ActRIIA
DWEHI cells did
not rescue the chemotactic response to BMP7 (Figure 5A, lane 11),
providing strong support for the idea that ActRIIB cannot, alone,
or in combination with endogenous BMPRII, mediate BMP7-
dependent chemotaxis.
Finally, we used the rescue assay to explore whether the
selective requirement for endogenous ActRIIA and BMPRII
subunits in BMP7-evoked chemotaxis is absolute. Expression of
exogenous BMPRII restored BMP7-evoked chemotaxis in
ActRIIA
DWEHI cells to ,70% of control activity (Figure 5A,
lane 12), indicating that when over expressed BMPRII counters
the effect of loss of ActRIIA. In reciprocal experiments, although
expression of wild-type, sh-BRII-sensitive, BMPRII failed to
restore BMP7-stimulated chemotaxis in BMPRII
DWEHI cells
(Figure 5B, lane 3), introduction of exogenous, wild-type
ActRIIA fully rescued the response to BMP7 (,90% recovery
of CI; Figure 5B, lane 4). Thus, although ActRIIA and BMPRII
are both essential mediators of the chemotactic response of
WEHI 274.1 cells to BMP7, at the non-physiological concentra-
tion achieved by transient over expression either receptor is
capable of sustaining the response alone. In contrast, ActRIIB is
not required for the chemotactic response and cannot support
this function.
BMP7-Evoked Chemotaxis Does Not Require Smad-
Dependent Signaling
Our results suggest that the chemotropic response of WEHI
274.1 cells to BMP7 depends on the selective engagement of
ActRIIA and BMPRII receptor subunits and raise the possibility
that engagement of this particular receptor complex results in
coupling selectively to an intracellular signaling pathway that
drives chemotaxis. All BMPs tested in this study stimulated R-
Smad phosphorylation, to similar levels, in WEHI 274.1 cells (see
Figure S2B), suggesting the differential ability of some BMPs to
stimulate chemotaxis is not imparted by selective activation of R-
Smads. However, our experiments did not distinguish between R-
Smad isoforms. Therefore to examine the role of the classical
Smad cascade further we asked whether the co-Smad, Smad4, a
key mediator of BMP-dependent gene transcription and down-
stream of R-Smad activation, is required for BMP7-evoked
chemotaxis.
A shRNA construct targeting Smad4 RNA (sh-Smad4) was
generated and tested for the ability to reduce expression and
activity of Smad4 in the classical BMP pathway. To test whether
the sh-Smad4 construct efficiently silences Smad4 function, we used
a common assay of BMP-evoked induction of the early response
gene Id1 in C2C12 myoblasts [35,36]. In C2C12 cells transfected
with sh-Smad4 (approximately 55% transfection efficiency mea-
sured by GFP expression), Smad4 protein levels decreased by 30%
(Figure 6A) and BMP7-stimulated induction of Id1 mRNA
expression was reduced by 46% (Figure 6B), demonstrating a
concurrent decrease in Smad4 expression and activity following sh-
Smad4 expression. We next tested the effects of sh-Smad4 in WEHI
274.1 cells, sorted to enrich for GFP-expressing cells. Smad4
protein expression was reduced in Smad4
DWEHI cells by 84%
relative to the dsRed
DWEHI cell population (Figure 6C). How-
ever, inhibition of Smad4 activity in WEHI 274.1 cells had no
effect on BMP7-stimulated chemotaxis (Figure 6D), suggesting an
alternate pathway underlies activation of cytoskeletal elements
mediating BMP7 stimulation of chemotaxis.
BMP7 Requires Activation of a Non-Canonical Signaling
Pathway
Divergence from the inductive pathway may reside in direct
coupling of an ActRIIA:BMPRII-containing receptor complex to
a cascade of cytoskeletal regulators or occur downstream of R-
Smad phosphorylation. The association of PI3K with BMP and
TGFb receptor subunits [24,37] and the dependence on PI3K
ActRIIA:BMPRII in Chemotaxis
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[27,28] led us to explore the possibility that BMP7 stimulates PI3K
activity and whether PI3K-dependent activity is required for
BMP7-evoked chemotropic responses.
The phosphorylation of Akt is a commonly used indicator of
PI3K activation [18]. We therefore measured Akt phosphoryla-
tion on S473 in WEHI 274.1 cells and found that BMP7
stimulated a robust phosphorylation (Figure 7A). To examine the
Figure 5. Rescue of shRNA-mediated inhibition of BMP7-stimulated chemotaxis by ActRIIA and BMPRII but not ActRIIB. A:
Chemotaxis in response to 10 pg/ml BMP7 (mean +/2 SEM) of dsRed
DWEHI cells (Lanes 1–5): alone (CI=77+/29, n=3) or co-expressing pcDNA3
(CI=69+/24, n=2), ActRIIA (CI=68+/214, n=3), ActRIIB (CI=63+/25, n=2) or BMPRII (CI=66+/26, n=2). These are compared with ActRIIA
DWEHI
cells (Lane 6–12): alone (CI=23+/26, n=3) or co-expressing pcDNA3 (CI=5+/21, n=3), wild-type ActRIIA (CI=28+/29, n=3), ActRIIA-RES-1V
(CI=38+/26, n=3), ActRIIA-RES-3V (CI=67+/214, n=3), ActRIIB (CI=5+/28, n=3) or BMPRII (CI=50+/210, n=3). B: Chemotaxis in response to
10 pg/ml BMP7 (mean +/2 SEM) of dsRed
DWEHI (CI=63+/27) and BMPRII
DWEHI (CI=11+/25) cells (Lanes 1 and 2) compared with BMPRII
DWEHI
cells co-expressing wild-type BMPRII (CI=16+/27) or ActRIIA (CI=58+/25) (Lanes 3 and 4). n=3 for each condition. BMP7-evoked chemotaxis in
ActRIIA
DWEHI cells expressing ActRIIA-RES-1V, ActRIIA-RES-3V or BMPRII differs significantly from chemotaxis in ActRIIA
DWEHI cells alone; (*) p,0.02
(Student’s t test). BMP7-evoked chemotaxis in BMPRII
DWEHI cells expressing wild-type ActRIIA differs significantly from chemotaxis in BMPRII
DWEHI
cells alone; (**) p,0.005 (Student’s t test).
doi:10.1371/journal.pone.0008198.g005
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WEHI 274.1 cells were pre-incubated with the PI3K inhibitors,
LY294002 (LY) or Wortmannin (WM), and then tested for their
ability to respond to BMP7. To control for non-specific effects of
LY or WM, the ability of BMP7 to stimulate phosphorylation of
R-Smads in the presence of the inhibitors was also tested. BMP7-
evoked phosphorylation of R-Smads by was unaffected by LY or
WM treatment (Figures 7B and S7A, respectively). In contrast, in
chemotaxis assays, both LY and WM treatment inhibited BMP7-
stimulated chemotaxis (LY: 85% reduction, Figure 7C and WM:
76% reduction, Figure S7B). Taken together, these data
demonstrate that stimulation of chemotaxis by BMP7 involves
Figure 6. Knockdown of Smad4 inhibits BMP7-evoked Id1 induction but not BMP7-evoked chemotaxis. A: Western blot analysis of
lysates of dsRed
DC2C12 and Smad4
DC2C12 cells, probed for expression of Smad4 and GFP (loading control) and showing 30% knockdown of
endogenous Smad4 (mean +/2 SEM, n=3). B: Northern analysis of mouse Id1 expression in control and 150 ng/ml BMP7-stimulated dsRed
DC2C12 and
Smad4
DC2C12 cells (Actin expression used as loading control). Smad4
DC2C12 cells show a 46% decrease in BMP7-evoked Id1 induction (mean +/2
SEM, n=4). C: Western blots of lysates from dsRed
DWEHI and Smad4
DWEHI cells, probed for expression of Smad4 and GFP (loading control),
demonstrate efficient knockdown of endogenous Smad4 by sh-Smad4 (84% reduction, mean +/2 SEM, n=3) in WEHI 274.1 cells. D D: dsRed
DWEHI and
Smad4
DWEHI cell chemotaxis in response to 10 pg/ml BMP7 did not differ (mean +/2 SEM, n=3). dsRed
DWEHI (CI=159+/233) v. Smad4
DWEHI
(CI=140+/241); p=0.745 (Student’s t test).
doi:10.1371/journal.pone.0008198.g006
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influences cytoskeletal reorganization through activation of
PI3K-dependent mechanisms.
Discussion
BMPs exert short latency, tropic effects on local cytoskeletal
dynamics, causing reorientation ofc e l l so rp a r t so fc e l l s ,s u c ha s
growth cones, as well as classical, long-term trophic effects
stimulating growth and differentiation. Such activities can
occur in the same cell, raising the question of how the distinct
responses to BMPs are transduced and whether components of
the classical pathway support both types of response. Here, we
demonstrate BMP agonist selectivity for chemotactic activity
and show that the type II BMP receptor subunits ActRIIA and
BMPRII mediate BMP7-evoked chemotaxis. This specific type
II receptor combination does not appear to be required for
BMP7-mediated activation of the Smad cascade and resulting
inductive activity. Our evidence suggests that the events
downstream of ActRIIA and BMPRII receptor subunit
activation, leading to chemotaxis, do not rely on Smad4-
dependent signaling but instead involve signaling through a
PI3K-dependent pathway. The concordance between the
identity of BMPs that can stimulate monocytic cell chemotaxis
and those that have reorienting activity in other cell types
suggests that the mechanism of engagement of a selective type II
receptor subunit pair in the receptor complex, leading to
activation of a Smad-independent intracellular pathway, may
have significance for the chemotropic activities of BMPs in a
wide range of cell types.
BMPs as Chemotropic Agents: Agonist Selectivity
A general issue in understanding the mechanisms underlying
the great variety of BMP inductive and tropic activities in the
developing and mature organism is that of how a large number of
BMPs act through a restricted number of BMP receptors to give
rise to many different outcomes. Selectivity may be provided by
diverse forms of agonist-receptor interaction that generate
differential downstream targeting [38–41]. The chemotropic
versus inductive effects of BMPs represent extreme examples in
the spectrum of this problem and knowledge of agonist selectivity
and transduction mechanisms are likely to illuminate the general
issue.
The BMPs examined in this study all have trophic activity
demonstrable by neural induction ability (see Figure S2A)
[11,32,33,42], by phosphorylation of R-Smads (see Figure S2B)
and by Smad4-dependent induction of Id1 (see Figure 6). They
presumably activate these transcriptional events through classical
pathways involving canonical BMP receptors. However, our
results show that it is not possible to predict chemotropic activity
of BMPs solely on the basis of their inductive activities. The
agonist selectivity that we observed is also surprising in the light of
structural considerations: BMP7, BMP2 and BMP4 were all active
in promoting chemotaxis yet belong to distinct structural
subgroups [30,31]. In contrast, BMP7 and BMP6 belong to the
same structural BMP subgroup (BMP5/6/7) and are 87%
identical, yet BMP6 was inactive in monocytic cell chemotaxis.
Nonetheless, the same activity profile has been observed for
reorientation of the growth cones of embryonic dorsal spinal
neurons ([11,12] and J. C. Perron and J. Dodd, unpublished),
providing support for the notion of a group of chemotropic BMPs,
Figure 7. PI3K activity is stimulated by BMP7 and required for BMP7-evoked chemotaxis. A: Western blots of whole cell lysates of WEHI
274.1 cells incubated with or without 50 ng/ml BMP7 were probed with a phospho-specific a-Akt(S) antibody. Measurement of total Akt and GAPDH
provided loading controls. Densitometric measurement (mean+/2SEM) shows an increase in response to BMP7 (70% over control n=2). B: Western
blots of whole cell lysates of control and 50 mM LY-treated WEHI 274.1 cells incubated with or without 50 ng/ml BMP7 were probed with a phospho-
specific a-Smad1/5/8 antibody. Measurement of total Smad and GAPDH provided loading controls. Inhibition of PI3K activity did not affect BMP7-
evoked stimulation of R-Smad phosphorylation. C: Chemotaxis (mean +/2 SEM) of WEHI 274.1 cells in response to 10 pg/ml BMP7 was significantly
reduced following 50 mM LY294002 (LY) treatment (85% reduction). BMP7-LY (CI=86+/215, n=3) v. BMP7+LY (CI=13+/23.5, n=3), p=0.0086
(Student’s t test). Treatment with LY alone had no effect on WEHI 274.1 cell movement under control conditions (LY alone: CI=3.5+/22.5, n=2; J. C.
Perron and J. Dodd, unpublished).
doi:10.1371/journal.pone.0008198.g007
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selective intracellular pathway leading to cytoskeletal reorganiza-
tion, and suggesting common underlying mechanisms.
Do chemotropic BMPs, typified by BMP7, and non-chemotro-
pic BMPs, such as BMP6, display different receptor binding
capacities? Studies in heterologous expression systems have shown
that BMP7 and BMP6 have the capacity to bind to the same type I
and type II BMP receptor subunits [19], although subtleties of
binding may be masked by the high concentrations achieved by
over expression, potentially concealing receptor specificity that
exists in a cell-specific context. For example, differences in affinity
or structure at receptor interfaces may account for differential
binding and, consequently, differential signaling by BMPs [41].
Nonetheless, selective binding of individual receptor subunits may
not alone explain the differential activities of closely related BMPs.
Specificity may lie rather in the recruitment of particular
combinations of subunits, such that chemotropic BMPs engage a
receptor complex whose composition is distinct from complexes
mediating inductive responses evoked by a majority of BMPs
(Figure 8). Alternatively, chemotropic BMPs may activate a
common receptor complex in a novel way, perhaps by also
engaging accessory proteins [43,44], that selectively transduces
information to the cytoskeleton.
Coordinated Type II BMP Receptor Subunit Activity
Mediates Acute Effects of BMP7
Our findings provide insight into the composition of the type II
BMP receptor subunit pair activated in the chemotropic response
to BMPs. The efficient knockdown of individual receptors in
WEHI 274.1 cells (70% ActRIIA, 60% ActRIIB, 45% BMPRII)
using RNAi provided a means to test the relative contributions of
the individual type II BMP receptor subunits. We show that all
three known type II BMP receptors are expressed by WEHI 274.1
cells but that only ActRIIA and BMPRII are required for function.
Knockdown of ActRIIB mRNA in WEHI 274.1 cells has no effect
on the chemotactic response to BMP7. Moreover, ActRIIB cannot
mediate a chemotactic response when over expressed in cells in
which ActRIIA is reduced. The demonstration that both ActRIIA
and BMPRII receptor subunits are selectively and individually
required for chemotactic activity argues against the idea that wild-
type levels of the remaining potential receptor subunit pairs,
homodimers of either ActRIIA or BMPRII, homodimers of
Figure 8. Model of differential receptor subunit recruitment and signaling underlying BMP-evoked chemotaxis and trophic actions.
We have demonstrated that ActRIIA and BMPRII receptor subunits are both selectively required for BMP7-evoked chemotaxis in monocytic cells. How
do the individual receptor subunits contribute to this activity? Do they work together in a common complex? A,B: Our data support a model in which
BMP7 engages both ActRIIA and BMPRII subunits either as part of a heteromeric type II receptor pair (A) or as homodimers, possibly forming unique
receptor complexes combining pairs of each of the type II receptor subunits (B). The identity of the type I receptors that contribute to this complex is
not known, although recent evidence implicates BMPRIB in BMP-dependent axon guidance [48,49]. Engagement of ActRIIA and BMPRII subunits by
chemotropic BMPs activates a signaling pathway leading to PI3K activity and cytoskeletal reorganization that is independent of Smad4-mediated
nuclear signaling. C: In contrast, BMP6 does not stimulate chemotaxis, presumably being unable to recruit or activate the ActRIIA:BMPRII complex
necessary for chemotropic signaling. In the same cell, however, BMP7 and BMP6 share the ability to activate Smad-dependent transcriptional
pathways, through receptor mechanisms that do not depend selectively on either ActRIIA or BMPRII.
doi:10.1371/journal.pone.0008198.g008
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BMPRII, independently mediate the chemotactic response.
Together, our findings therefore fit best with a scheme in which
chemotropic BMPs, typified by BMP7, engage a receptor complex
in which the type II component is a heterodimer of ActRIIA and
BMPRII (Figure 8A). Nevertheless, the incomplete knockdown of
ActRIIB achieved in our experiments leaves open the possibility
that this receptor subtype contributes in some way to the
chemotactic response, albeit at a different threshold than that of
ActRIIA and BMPRII.
The notion of selective subunit pairing to produce different
signaling outcomes extends the finding that recruitment of
different combinations of type I and type II subunit homodimers
that couple to distinct downstream signaling pathways underlies
some of the differential activities of the TGFb superfamily [38,45].
However, previous work in many systems has emphasized the roles
of homomeric pairs of type I and type II receptor subunits in BMP
signaling and, for a variety of technical reasons, the potential role
of heteromeric pairings has not been addressed. Studies in which
the specific association of a type I BMP receptor with existing
clusters of BMPRII is necessary for the initiation of efficient Smad
signaling [39,40], emphasize the importance of understanding the
mode of receptor complex oligomerization in directing signaling
outcomes for distinct ligands and receptors. The heterodimeric
model above (Figure 8A) assumes that, like other BMP receptor
complexes [19,20], only two type II subunits contribute to the
complex. However, the results of the rescue experiments described
here (see Figure 5) indicate that, at high enough concentration,
homodimers of either ActRIIA or BMPRII, but not ActRIIB, can
support BMP7-dependent chemotaxis. Although the non-physio-
logical levels of receptor subunits produced by over expression
might only artificially allow type II BMP receptor homodimers to
mediate the chemotactic response to BMP7, this finding raises the
possibility that a threshold level of cell surface receptor expression,
comprising either ActRIIA or BMPRII homodimers, is sufficient
for a chemotactic response to BMPs. As described above, we show
that in the context of either ActRIIA or BMPRII knockdown, the
unaffected, endogenous type II BMP receptor is unable to
compensate for the loss of the other. Nonetheless, the levels of
activity achieved by the coordinate activation of endogenous
ActRIIA and BMPRII homodimers in wild-type conditions may
be sufficient to elicit a chemotactic response. Such a model
(Figure 8B) would require the formation of a receptor complex
comprising multiple pairs of subunits and appropriate BMP dimer
orientation. This notion of a multi-unit complex represents a less
parsimonious model than that of a complex in which the type II
receptor pair consists of a heterodimeric ActRIIA:BMPRII unit
(Figure 8A). However, neither model can be dismissed on the
current evidence.
The observed selectivity in type II BMP receptor activity in
chemotaxis raises two further questions about the formation of
receptor complexes. First, how do certain BMPs recruit the
ActRIIA and BMPRII receptor subunit pair? Although the
selection of downstream signaling pathways has previously been
shown to be determined by whether BMPs actively recruit
individual receptor subunits sequentially to the ligand/receptor
complex or bind to preformed type II/type I receptor pairs
[39,40], it is not clear how this specificity is achieved. Our results
do not yet address this issue. Second, how are type I BMP receptor
subunits are involved? Type I receptors have generally been
associated with Smad-dependent transcriptional signaling and
thought to play an instructive role in the induction of cell fate by
BMPs [46,47]. However, two recent studies have implicated type I
receptor subunits in axon guidance by BMPs [48,49] suggesting
that recruitment of canonical BMP receptor subunits to the
chemotropic pathway may engage both type I and type II
receptors. Nonetheless, the demonstration that BMPs bind to
preformed pairs of receptors present in the cell membrane [40]
leaves open the possibility that type I BMP receptors play a passive
role, and that the chemotactic response to BMPs in monocytes is
directed by type II BMP receptor pairs.
Smad4-Independent PI3K Signaling Mediates BMP7-
Activated Chemotaxis
How does receptor activation by BMP7 lead to the cellular
response culminating in directed cell migration? Is there a
dedicated intracellular pathway activated by an ActRIIA:BMPRII
receptor complex or does the targeting of the cytoskeleton develop
as a branch downstream in the canonical pathway? Several lines of
evidence support the idea that BMP7-evoked chemotaxis of
WEHI 274.1 cells does not depend on Smad signaling. Like other
cells that show chemotropic responses to BMPs, the onset of
chemotaxis is too rapid to depend on classical Smad-mediated
transcription, translation, maturation and transport of functional
protein to the relevant cellular compartment. Moreover, chemo-
taxis occurs in response to BMPs at concentrations 10–100-fold
less than that required for gene induction [7]. Importantly, direct
reduction of Smad4 expression and activity has no effect on
BMP7-evoked chemotaxis. Finally, R-Smad phosphorylation is
robust despite knockdown of individual receptors and loss of
chemotaxis. Although we cannot formally exclude a non-
transcriptional role for R-Smads in the chemotactic response,
BMP6 and GDF7 do not stimulate chemotaxis in WEHI 274.1
cells, yet BMP7, BMP6 and GDF7 all stimulate R-Smad
phosphorylation similarly, making it unlikely that the divergence
of signaling pathways originates with R-Smad activation. Con-
versely, we find that BMP7 stimulates PI3K activity and that there
is a requirement for PI3K-dependent signaling in BMP7-evoked
chemotaxis but not for BMP7-evoked Smad phosphorylation.
These results complement the emerging evidence that members
of the TGFb superfamily, which includes BMPs, regulate
cytoskeletal dynamics through Smad-independent intracellular
mechanisms. Immunoprecipitation studies have demonstrated an
association of the p85 regulatory subunit of PI3K with type II
BMP receptors as well as with TGFb receptors [24,37] suggesting
that type II BMP receptors may directly stimulate PI3K activity
and thus play a role in the generation of acute BMP responses.
PI3K activity represents a common step in chemotaxis evoked by a
number of distinct ligands and it is not yet clear how directly the
binding of BMP7 to ActRIIA and BMPRII receptor subunits leads
to activation of PI3K. Regardless, Smad4 and PI3K appear to
represent components of two divergent signaling paths, one
controlling transcriptional activity and the other that gives rise
to rapid, directed cell migration. Notably, both PI3K and the small
GTPase, Cdc42, appear to be required for the complex but rapid
BMP2-mediated stimulation of actin assembly and formation of
protrusions during C2C12 myoblast migration [18]. Moreover,
TGFb1 and BMP7 have been shown to stimulate members of the
LIMK and Rho GTPase families, influencing cell morphology and
actin reorganization, dendritogenesis and growth cone guidance
[13,25,50,51]. Several Smad-independent pathways appear there-
fore to be activated downstream of BMPs in events relying on
dynamic regulation of the cytoskeleton.
In summary, the chemotropic effects of BMPs in the WEHI
274.1 cell model system appear to be mediated by canonical BMP
receptors combining and responding in non-classical ways to
activate Smad4-independent signaling. ActRIIA and BMPRII
are required, apparently in a novel heteromeric or multimeric
ActRIIA:BMPRII in Chemotaxis
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ability of BMP7 to evoke Smad-dependent signaling and
chemotropic responses in the same cells suggests intricate
regulation of these mechanisms. Our findings provide support
for the possibility that chemotropic BMPs recruit selectively type II
BMP receptor subunits with the capacity to initiate local
cytoskeletal signaling.
Materials and Methods
Antibodies and Reagents
Recombinant BMPs were purchased from R&D Systems,
MCP-1 from Sigma. Antibodies: mouse a-Smad4 (B8), goat a-
ActRIIA (N17), rabbit a-ActRIIB (H70) (Santa Cruz), mouse
a-BMPRII (BD Transduction Laboratories), rabbit a-phospho-
Smad1/5/8, rabbit a-phospho-Akt(S) and rabbit a-Akt (Cell
Signaling Technology), rabbit a-Smad1 (Upstate Biotechnology),
rabbit a-GFP (Molecular Probes) and rabbit a-GAPDH (Abcam).
HRP-conjugated secondary antibodies (HRP goat a-rabbit IgG,
HRP goat a-mouse Fcc, and HRP donkey a-goat IgG) were
obtained from Jackson Labs. The receptor antibodies were unable
to recognize endogenous receptor protein in WEHI 274.1, HEK
293 or COS-1 cells. Cell culture reagents: DMEM medium, 100x
Penicillin/Streptomycin/Glutamine (P/S/G) (Invitrogen) and
FBS (Gemini BioProducts). The expression construct for flag-
tagged mouse ActRIIA cDNA, subcloned into pcDNA3, was
generously provided by Dr. K. Miyazono (The JFCR Cancer
Institute). Human BMPRII and partial mouse ActRIIB cDNA
clones were obtained from ATCC. BMPRII cDNA construct was
tagged with a C-terminal HIS tag and subcloned into the
pCAGGS vector. A full length flag-tagged ActRIIB cDNA was
obtained by RT-PCR from adult mouse brain and subcloned into
the pCMVTag4 vector (Stratagene).
Chemotaxis Assays
The WEHI 274.1 mouse monocytic cell line and the THP-1
human leukemia cell line (ATCC) were maintained in standard
growth medium (DMEM/10% FBS/1x P/S/G). Cells were
washed twice in nonsupplemented DMEM medium, counted
using a hemocytometer, resuspended to 2610
6 cells/ml in serum-
free medium and pre-incubated for 1 hour at 37uC. For PI3K
inhibitor experiments, 50 mM LY294002 (Cell Signaling Tech-
nology) or 100 nM Wortmannin (Sigma) was added to the cells
during the pre-incubation period. WEHI 274.1 cells (100 ml) were
then added to the upper chamber of 24-well, 5 mm transwell filter
inserts (Costar) and 600 ml of recombinant BMP or MCP-1 diluted
in nonsupplemented DMEM added to the lower chamber. BMPs
have been shown to be potent chemotactic agents with maximal
stimulation of human monocytes around 0.1–1 pg/ml (3–30 fM)
[7,8]. Our dose response curve confirms these findings and for
routine experiments 1 pg/ml or 10 pg/ml was used. After 30
minutes at 37uC, the filter inserts were washed in PBS, fixed with
2.5% gluteraldehyde (Sigma) and stained with Gill’s Hemotoxylin
(Sigma) as per the manufacturer’s instructions. The filters were
mounted onto glass microscope slides in 50% glycerol and
coverslipped. Cells within the filter pores were counted from 4
fields (viewed at 20x) each from duplicate or triplicate filters
(1000–3000 cells/filter) using a Zeiss Axiovert inverted micro-
scope. Results are presented as the chemotaxis index (CI) = ((#
treated cells in filter pores) 2 (# control cells in filter pores)/(#
control cells in filter pores))6100 (mean +/2 SEM).
Zigmond-Hirsh checkerboard analysis was used to assess the
chemotactic versus chemokinetic response of WEHI 274.1 cell
migration to BMP7 by varying the concentration of BMP7 in both
the upper and lower transwell chambers [52].
RT-PCR for Type II BMP Receptors
Primers for the 3 mouse type II receptor subunits (ActRIIA,
ActRIIB, and BMPRII) were used as previously described [53].
Total RNA (Trizol Reagent, Invitrogen) was prepared from
suspension cultures of WEHI 274.1 cells. Reverse transcription of
RNA (2 mg) was performed using oligo dT primers and
Superscript II reverse transcriptase (Invitrogen). Amplification of
individual type II BMP receptor fragments was performed for each
primer set using 5 Prime MasterMix (5 Prime, Inc.).
Design and Construction of shRNA Vectors
For RNAi-mediated down-regulation of type II BMP receptor
subunits, synthetic oligonucleotides were designed to target
sequences 100% conserved in human, mouse and rat ActRIIA,
BMPRII and Smad4, using shRNA design guidelines [54] and the
RNAi design program at the Whitehead institute (http://jura.wi.
mit.edu). Oligonucleotides were annealed and ligated into the
LentiLox3.7 lentiviral vector (pLL3.7, generously provided by Dr.
L. Van Parijs, MIT) under the control of the U6 promoter [55]
and used to produce shRNAs for the specific targets. This plasmid
also encoded EGFP under the control of the CMV promoter,
effectively tagging all shRNA-expressing cells. Target sequences
were as follows: ActRIIA (sh-AIIA -5 9 GCAGGAAGTTGTT-
GTGCAT 39), BMPRII (sh-BRII -5 9 GGATGAGCGTCCA-
GTTGCT 39) and Smad4 (sh-Smad4 -5 9 ACAATGAGCTTG-
CATTCCA 39). A lentiviral shRNA construct, targeting the
mouse ActRIIB receptor (sh-AIIB), was obtained from Open
Biosystems (clone ID# TRCN0000022641). Test transfections of
the shRNA constructs were performed by Lipofectamine (Invitro-
gen) transfection into HEK 293 and COS-1 cells. sh-dsRed,
targeting red fluorescent protein, was used as a functional negative
control (sh-dsRed -5 9 GCAGCGTCGTTCGATACTA 39). sh-
BRII, sh-Smad4, and sh-dsRed constructs were generously provided
by Dr. P. Scheiffele, Columbia University. sh-AIIA-resistant
ActRIIA cDNAs were produced by site-directed mutagenesis of
1 or 3 Valine codons in the sequence targeted by sh-AIIA,
ActRIIA-RES-1V (V431V) or ActRIIA-RES-3V (V431V, V432V,
V433V), respectively, using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene).
Electroporation and Cell Sorting
WEHI 274.1 cells were washed twice in nonsupplemented
DMEM, added to a 4 mm electroporation cuvette (0.8 ml at
1.2610
7 cells/ml) with GFP-tagged shRNA vectors (20 mg),
cDNA expression constructs (20 mg) or empty vector (20 mg) for
control experiments and incubated for 15 minutes at 37uC. Cells
were electroporated at 340 V, 960 mF using a BioRad GenePulser.
Cells were left to recover (10 minutes, 37uC), then plated in 20 ml
fresh growth medium for 12 hours and washed. GFP positive cells
were subjected to fluorescence-activated cell sorting (FACS) (Ultra
Hypersort Flow Cytometer, Beckman Coulter). Sorted cells
(
DWEHI) were washed in fresh growth medium and plated for
12 hours before harvesting for chemotaxis assays and Western
analyses.
Quantitative PCR (QPCR)
One microgram of total RNA (Trizol Reagent, Invitrogen),
isolated from sorted, shRNA-expressing WEHI 274.1 cells, was
reverse-transcribed using RevertAid First Strand cDNA Synthesis
Kit (Fermentas). For individual experiments (n=2), three 20 ml
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pooled. A single 20 ml cDNA reaction was prepared in the absence
of reverse transcriptase (No RT control). Real-time QPCR was
performed on the Mx3000P QPCR apparatus and analyzed on
MxPro-Mx3000P v4.0 software (Stratagene). Serial dilutions of
wild-type WEHI 274.1 cDNA were used to determine the
amplification efficiency for each primer set (see Table 1) using
2X Maxima SYBR Green qPCR Master Mix (Fermentas).
Reaction conditions were as follows: denaturation for 10 minutes
at 95uC, followed by 40 cycles of 30 seconds at 95uC, 1 minute at
58uC, and 1 minute at 72uC. Comparative quantitative analysis
was performed using b-actin as a normalizing control and
expressed relative to BMP receptor mRNA levels in dsRed
D
WEHI
cells. Three individual comparative analyses, which included No
RT and No Template controls, were performed on each set of
pooled cDNA.
Western Blot Analysis
Whole cell lysates were prepared using 1x Lysis Buffer (Cell
Signaling Technology). Samples were separated by SDS-PAGE
(EZ-Run Gel Solution, Fisher Scientific) and transferred to
nitrocellulose (Whatman). Nitrocellulose membranes were blocked
in 5% non-fat milk/0.1% Tween 20/TBS (Blocking Buffer) and
probed overnight with primary antibodies diluted in Blocking
Buffer. Membranes were washed in TBST (0.1% Tween 20/TBS)
and probed (1 hour) with HRP-conjugated secondary antibodies
in Blocking Buffer. After washing in TBST, blots were developed
using the Supersignal West Pico chemiluminescent substrate
detection kit (Pierce). Densitometric analysis was performed using
ImageJ 1.37v software (NIH).
For phosphorylation assays, WEHI 274.1 cells were stimulated
with BMPs for 30 minutes before preparation of cell lysates.
Membranes were blocked and the primary and secondary
antibodies diluted in 5% non-fat milk/0.1% Tween 20/TBS,
except for the phospho-Smad1/5/8 and phospho-Akt(S) antibod-
ies which were diluted in 5% BSA/0.1% Tween 20/TBS.
Northern Analysis
The C2C12 myoblast cell line (ATCC) was maintained in
standard growth medium (DMEM/10% FBS/1x P/S/G). The
cells were transfected with sh-dsRed or sh-Smad4 using Lipofecta-
mine Reagent (Invitrogen). Following transfection, the cells were
incubated overnight in serum-free OptiMEM supplemented with
1x P/S/G. Cells were then stimulated with 150 ng/ml BMP7 for
1 hour. Total RNA was extracted from each sample using Trizol
Reagent (Invitrogen). Ten micrograms of total RNA was separated
on a MOPS/formaldehyde gel, transferred to nylon membrane
(GeneScreen Plus, Perkin Elmer) and hybridized with a digox-
igenin-labeled RNA antisense probe, generated from a mouse Id1
cDNA construct (NIH Mammalian Gene Collection, Invitrogen).
Digoxigenin labeling of the probe, hybridization, and chemilumi-
nescent detection were performed using the DIG Northern Starter
Kit and the DIG Wash and Block Buffer Set (Roche). BMPs have
been shown to be potent chemotactic agents with maximal
stimulation of human monocytes around 0.1–1 pg/ml (3–30 fM)
[7,8]. In contrast, BMP concentrations required to stimulate Smad
phosphorylation or induce gene expression are considerably
higher [7,11].
Supporting Information
Figure S1 THP-1 cell migration through transwell chamber
filters in response to 10 pg/ml BMP7, BMP2, BMP6 or GDF7 in
the lower chamber. For comparison, cells were also stimulated
with MCP-1 (100 ng/ml). Results are presented as the chemotaxis
index (CI) = ((# treated cells in filter pores) 2 (# control cells in
filter pores)/(# control cells in filter pores))6100 (mean +/2
SEM). MCP-1 (CI=71+/218, n=3); BMP7 (CI=125+/231,
n=4); BMP2 (CI=89+/221, n=3); BMP6 (CI=4+/217, n=2);
GDF7 (CI=6+/210, n=2).
Found at: doi:10.1371/journal.pone.0008198.s001 (0.14 MB TIF)
Figure S2 A: Stage 10 chick [1] intermediate spinal cord
explants were isolated and cultured in three-dimensional collagen
gels in OptiMEM medium supplemented with 1x Penicillin/
Streptomycin/Glutamine (Invitrogen) as previously described [2].
Explants were incubated in control medium (No Rx) or 10 ng/ml
BMP7, BMP6 or GDF7 (R&D Systems) for 48 hours, fixed in 4%
paraformaldehyde (Electron Microscopy Sciences) and labeled
with a rabbit a-LH2 (L1) antibody and a Cy3-conjugated goat-a-
rabbit secondary antibody (Jackson Labs). Z-stack images were
obtained on a Zeiss LSM510 confocal microscope. BMP7, BMP6
and GDF7 induced similar levels of LH2 expression. B: Whole cell
lysates of WEHI 274.1 cells incubated with or without 50 ng/ml
BMP7, BMP6 or GDF7 were probed on Western blots with a
phospho-specific a-Smad1/5/8 antibody. GAPDH expression
served as a loading control. Results are expressed as the percent
of control (mean +/2 SEM) for each condition relative to pSmad
levels in control (No Rx) cells (n=3). BMP7, BMP6 and GDF7
stimulated the phosphorylation of R-Smads to similar levels
(,40% over control). References: [1] Hamburger V, Hamilton H
(1951) A series of normal stages in the development of chick
embryo. J Morphol 88: 49–92. [2] Yamada T, Placzek M, Tanaka
H, Dodd J, Jessell TM (1991) Control of cell pattern in the
developing nervous system: polarizing activity of the floor plate
and notochord. Cell 64: 635–647.
Found at: doi:10.1371/journal.pone.0008198.s002 (0.68 MB TIF)
Figure S3 Western analysis of COS-1 whole cell lysates co-
expressing control constructs and type II BMP receptor cDNA. A-
C: Co-expression of ActRIIA (A), ActRIIB (B) or BMPRII (C) with
sh-dsRed does not affect the level of receptor protein expression
observed with empty vector (pLL3.7) co-expression. GAPDH
expression served as a loading control.
Found at: doi:10.1371/journal.pone.0008198.s003 (0.37 MB TIF)
Figure S4 Western analysis of whole cell lysates of HEK 293
cells, co-transfected with type II BMP receptor shRNAs or sh-dsRed
and cDNA expression constructs, using a-ActRIIA, a-ActRIIB, or
a-BMPRII antibodies, as indicated. These antibodies do not detect
endogenous HEK 293 cell receptor protein, necessitating the use
of a heterologous expression system to measure protein regulation
in response to shRNA expression (J. C. Perron and J. Dodd,
Table 1. Primers for real-time quantitative PCR.
Target Primers Reference
ActRIIA GTTGAACCTTGCTATGGTGATAA,
AATCAGTCCTGTCATAGCAGTTG
[56]
ActRIIB CACAAGCCTTCTATTGCCCACAG,
CATGTACCGTCTGGTGCCAAC
[57]
BMPRII TGGCAGTGAGGTCACTCAAG,
TTGCGTTCATTCTGCATAGC
[58]
b-actin TGCGTGACATCAAAGAGAAG,
GATGCCACAGGATTCCATA
[59]
Sequences and literature references for primer sets used in QPCR.
doi:10.1371/journal.pone.0008198.t001
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normalized to GFP or GAPDH and expressed relative to receptor
expression levels in sh-dsRed transfected cells (mean +/2 SEM,
n=3 for each condition). A–C: Relative ActRIIA protein levels in
cells co-expressing ActRIIA cDNA and sh-AIIA (A), sh-AIIB (B) or
sh-BRII (C). Quantitation, shown in histograms, shows that sh-AIIA
inhibited ActRIIA expression by 90% (A). D–F: Relative ActRIIB
protein levels in cells co-expressing ActRIIB cDNA and sh-AIIA
(D), sh-AIIB (E) or sh-BRII (F). sh-AIIB inhibited ActRIIB
expression by 45% (E). G–I: Relative BMPRII protein levels in
cells co-expressing BMPRII cDNA and sh-AIIA (G), sh-AIIB (H) or
sh-BRII (I). sh-BRII inhibited BMPRII expression by 80% (I). The
type II BMP receptor shRNAs modulated target subunit protein
selectively. Non-target BMP receptor expression was unchanged
for all combinations with one exception: although sh-AIIB had no
effect on BMPRII expression (H), expression of exogenous,
flag-tagged mouse ActRIIA increased (B). These results were
replicated using epitope tag antibodies to identify the individual
heterologously expressed receptors (J. C. Perron and J. Dodd,
unpublished).
Found at: doi:10.1371/journal.pone.0008198.s004 (0.86 MB TIF)
Figure S5 dsRed
D
2, ActRIIA
D
2, ActRIIB
D
2 and BMPRII-
WEHI cells were tested for R-Smad phosphorylation in response
to 50 ng/ml BMP7 for 30 minutes at 37uC. Whole cell lysates
were probed on Western blots with a phospho-specific a-Smad1/
5/8 antibody. Total Smad, GAPDH, and GFP expression served
as loading controls.
Found at: doi:10.1371/journal.pone.0008198.s005 (0.57 MB TIF)
Figure S6 Western analysis and quantitation of COS-1 cell co-
transfections of sh-dsRed or sh-AIIA with wild-type ActRIIA cDNA
and co-transfection of sh-AIIA with either ActRIIA-RES-1V or
ActRIIA-RES-3V mutant cDNAs. ActRIIA-RES-1V and Ac-
tRIIA-RES-3V mutant cDNAs both showed resistance to the
activity of sh-AIIA; ActRIIA-RES-1V (22% reduction) and Ac-
tRIIA-RES-3V (2% reduction) compared to wild-type ActRIIA
(90% reduction) in the presence of sh-AIIA. Results are expressed as
the percent of control (mean +/2 SEM) for each condition relative
to ActRIIA protein in sh-dsRed-expressing cells (control) cells (n=3
for each condition). GFP expression served as a loading control.
Found at: doi:10.1371/journal.pone.0008198.s006 (0.31 MB TIF)
Figure S7 A: Western blots of whole cell lysates of control and
100 nM Wortmannin (WM)-treated WEHI 274.1 cells, incubated
with or without 50 ng/ml BMP7 for 30 minutes, were probed with
a phospho-specific a-Smad1/5/8 antibody. Measurement of total
Smad and GAPDH provided loading controls. Inhibition of PI3K
activity did not affect BMP7-evoked stimulation of R-Smad
phosphorylation. B: Chemotaxis of WEHI 274.1 cells in response
to 10 pg/ml BMP7 was significantly reduced following 100 nM
WM treatment (78% reduction). Results are expressed as the
mean +/2 SEM. BMP7-WM (CI=56+/27, n=3) v. BMP7+
WM (CI=13+/23, n=3), p=0.0042 (Student’s t test). Treat-
ment with WM alone (control conditions) had no effect on WEHI
274.1 cell movement (CI=3.7+/23.5, n=2; J. C. Perron and J.
Dodd, unpublished).
Found at: doi:10.1371/journal.pone.0008198.s007 (0.33 MB TIF)
Table S1 Migration of WEHI 274.1 cells was measured in
response to manipulation of BMP7 concentration gradients in
transwell chemotaxis assays (value = Chemotaxis Index = ((#
treated cells in filter pores) 2 (# control cells in filter pores)/(#
control cells in filter pores))6100, mean +/2 SEM, n$3 for each
condition). Distinct gradients (G) were generated by placing high
and low concentrations of BMP7 in upper and/or lower
chambers, as indicated (G= [x:y], where x and y represent the
concentration of BMP7 in the upper and lower chambers,
respectively; 0 = No treatment, 1p = 1 pg/ml BMP7 and
100n = 100 ng/ml BMP7). Neutralization of the concentration
gradient (bold numbers), by addition of equal concentrations of
BMP7 to the upper and lower compartments (i.e. G= [1p:1p]o r
G= [100n:100n]), reduced the response to control levels. 1 pg/ml
BMP7 in the lower chamber (G= [0:1p]) significantly stimulated
WEHI 274.1 cell migration towards the source of BMP7
compared to migration observed in the absence of a gradient of
BMP7 (p=0.00038 for [0:1p]v .[ 1p:1p]), demonstrating that
BMP7 acts as a chemoattractant at this concentration. 1 pg/ml
BMP7 in the upper chamber only (G= [1p:0]) did not evoke
migration through the filter (p=0.626 for [1p:0]v .[ 1p:1p]),
indicating that BMP7 does not simply increase baseline chemo-
kinetic activity of WEHI 274.1 cells. The presence of high
concentrations of BMP7 in the lower chamber (G= [0:100n])
markedly inhibited WEHI 274.1 cell movement into the transwell
filter compared to migration in the absence of a BMP7 gradient
(p=0.0075 for [0:100n]v .[ 100n:100n]). In contrast, migration
towards the lower chamber was stimulated when 100 ng/ml
BMP7 was added to the cells in the upper chamber (G= [100n:0])
demonstrating a chemorepellent activity of BMP7 at high
concentrations. The observed increase in chemotaxis in response
to 100 ng/ml BMP7 in the upper chamber, however, was not
quite significantly different from chemotaxis in the absence of a
BMP7 gradient (p=0.059 for [100n:0]v .[ 100n:100n]). Together,
these results show that BMP7 stimulates chemotaxis in WEHI
274.1 monocytic cells, the direction of which is dependent on the
BMP concentration. ND = Not Determined.
Found at: doi:10.1371/journal.pone.0008198.s008 (0.03 MB
DOC)
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